For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Veracyte Inc’s stock clocked out at $44.61, down -5.91% from its previous closing price of $47.41. In other words, the price has decreased by -$5.91 from its previous closing price. On the day, 1.07 million shares were traded. VCYT stock price reached its highest trading level at $47.45 during the session, while it also had its lowest trading level at $44.14.
Ratios:
To gain a deeper understanding of VCYT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.91. For the most recent quarter (mrq), Quick Ratio is recorded 5.94 and its Current Ratio is at 6.23. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On October 20, 2025, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $40.
On March 20, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $45.Craig Hallum initiated its Buy rating on March 20, 2025, with a $45 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 05 ’25 when KARIN EASTHAM bought 20,000 shares for $47.41 per share.
McGuire Annie sold 1,422 shares of VCYT for $67,261 on Dec 04 ’25. The SVP, General Counsel now owns 78,499 shares after completing the transaction at $47.30 per share. On Dec 04 ’25, another insider, Chambers Rebecca, who serves as the Chief Financial Officer of the company, sold 13,278 shares for $46.84 each. As a result, the insider received 621,955 and left with 109,496 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 3526383872 and an Enterprise Value of 3200408576. As of this moment, Veracyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 117.49, and their Forward P/E ratio for the next fiscal year is 27.62. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.12 while its Price-to-Book (P/B) ratio in mrq is 2.80. Its current Enterprise Value per Revenue stands at 6.464 whereas that against EBITDA is 43.017.
Stock Price History:
The Beta on a monthly basis for VCYT is 1.87, which has changed by 0.043264747 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, VCYT has reached a high of $50.71, while it has fallen to a 52-week low of $22.61. The 50-Day Moving Average of the stock is 14.25%, while the 200-Day Moving Average is calculated to be 40.17%.
Shares Statistics:
It appears that VCYT traded 967.96K shares on average per day over the past three months and 1018730 shares per day over the past ten days. A total of 79.03M shares are outstanding, with a floating share count of 77.32M. Insiders hold about 2.24% of the company’s shares, while institutions hold 111.61% stake in the company. Shares short for VCYT as of 1763078400 were 5450021 with a Short Ratio of 5.63, compared to 1760486400 on 6722370. Therefore, it implies a Short% of Shares Outstanding of 5450021 and a Short% of Float of 7.6899999999999995.
Earnings Estimates
Veracyte Inc (VCYT) is currently under the scrutiny of 11.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.34, with high estimates of $0.44 and low estimates of $0.27.
Analysts are recommending an EPS of between $1.67 and $1.6 for the fiscal current year, implying an average EPS of $1.65. EPS for the following year is $1.6, with 11.0 analysts recommending between $2.08 and $1.21.
Revenue Estimates
In. The current quarter, 11 analysts expect revenue to total $131.73M. It ranges from a high estimate of $133.2M to a low estimate of $130.6M. As of. The current estimate, Veracyte Inc’s year-ago sales were $118.63MFor the next quarter, 11 analysts are estimating revenue of $130.43M. There is a high estimate of $134.4M for the next quarter, whereas the lowest estimate is $124.1M.
A total of 12 analysts have provided revenue estimates for VCYT’s current fiscal year. The highest revenue estimate was $509.8M, while the lowest revenue estimate was $507.1M, resulting in an average revenue estimate of $508.32M. In the same quarter a year ago, actual revenue was $445.76MBased on 12 analysts’ estimates, the company’s revenue will be $565.85M in the next fiscal year. The high estimate is $580.5M and the low estimate is $553.48M.
